Cure51, a technology company seeking to unlock the biological mechanisms responsible for exceptional survival among cancer patients, has received investment. It announced that it has successfully raised €15 million in a seed funding round led by Sofinnova Partners. Other investors included Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel and Olivier Pomel, CEO and co-founder of Datadog.
Also See: What happened in the startup ecosystem this week?
Cure51
It will enable Cure51 to create a unique group investigating the molecular processes that enable certain cancer patients to survive for very long despite having highly aggressive forms of the disease. The company aims to unlock these mechanisms to enable every patient to become an exceptional survivor through new insights into precision drug and drug target discovery. The key to this endeavour are novel analytical techniques and the company's strong partnership with leading oncology centres around the world.
Cure51 was founded in March 2022 by Nicolas Wolikow and Simon Istolainen alongside experienced entrepreneurs and four world-renowned oncology centres. Gustave Roussy Institute (IGR, Paris - France), Leon Bérard Centre (CLB, Lyon - France), Charité Universitätsmedizin (Berlin - Germany) and Vall d'Hebron (VHIO, Barcelona - Spain).
What is the aim? To rewrite the story of cancer, leading to the creation of the world's first global clinical and molecular database of cancer survivors. Instead of focusing on disease mechanisms, it looks at outliers - individuals who defy statistics and miraculously survive the most aggressive forms of cancer, including metastatic stage pancreatic cancer and glioblastoma.
No comments yet for this news, be the first one!...